search
Back to results

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

Primary Purpose

Mycobacterium Avium-intracellulare Infection, HIV Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Clofazimine
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mycobacterium Avium-intracellulare Infection focused on measuring AIDS-Related Opportunistic Infections, Mycobacterium avium-intracellulare Infection, Clofazimine, Acquired Immunodeficiency Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Pneumocystis prophylaxis. Antiretroviral therapy, or other experimental protocols. Antipyretics and analgesics as per the treating physician. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 g percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Patients with the following are excluded: Known hypersensitivity to clofazimine. Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation from stool in asymptomatic patient). Any of the following symptoms at the time of study entry: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC activity. Prior Medication: Excluded: Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Group 1: AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2 to 4 months prior to study entry. Group 2: Patients with T4 counts < 100 cells/mm3, regardless of prior opportunistic infections or malignancies. Karnofsky = or > 70. All patients must sign informed consent.

Sites / Locations

  • Keith Med Group
  • San Francisco Gen Hosp

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT00002058
Brief Title
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
Official Title
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
Study Type
Interventional

2. Study Status

Record Verification Date
December 1990
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of California, San Francisco

4. Oversight

5. Study Description

Brief Summary
This study will examine the effectiveness of clofazimine in the prophylaxis of Mycobacterium avium complex infection in HIV infected individuals who are at risk to develop this untreatable opportunistic disease. In the absence of truly effective antiretroviral therapy, a potential mode of treatment of patients with HIV infection is to prevent the development of the life-threatening opportunistic infections. Current studies demonstrate a possible efficacy of clofazimine in the prophylaxis against Pneumocystis carinii pneumonia (PCP), the most common AIDS-defining opportunistic infection. Future studies will examine the potential for prophylaxis against the other opportunistic infections. This proposal hopes to define the role of prophylactic clofazimine in preventing the currently untreatable Mycobacterium avium complex infection. AMENDED: To include prophylaxis for Asymptomatic and ARC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mycobacterium Avium-intracellulare Infection, HIV Infections
Keywords
AIDS-Related Opportunistic Infections, Mycobacterium avium-intracellulare Infection, Clofazimine, Acquired Immunodeficiency Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Clofazimine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Pneumocystis prophylaxis. Antiretroviral therapy, or other experimental protocols. Antipyretics and analgesics as per the treating physician. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 g percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Patients with the following are excluded: Known hypersensitivity to clofazimine. Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation from stool in asymptomatic patient). Any of the following symptoms at the time of study entry: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC activity. Prior Medication: Excluded: Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Group 1: AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2 to 4 months prior to study entry. Group 2: Patients with T4 counts < 100 cells/mm3, regardless of prior opportunistic infections or malignancies. Karnofsky = or > 70. All patients must sign informed consent.
Facility Information:
Facility Name
Keith Med Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
San Francisco Gen Hosp
City
San Francisco
State/Province
California
ZIP/Postal Code
941102859
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
2152803
Citation
Gustavson LE, Fukuda EK, Rubio FA, Dunton AW. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr (1988). 1990;3(1):28-31.
Results Reference
background
PubMed Identifier
8501340
Citation
Abrams DI, Mitchell TF, Child CC, Shiboski SC, Brosgart CL, Mass MM. Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis. 1993 Jun;167(6):1459-63. doi: 10.1093/infdis/167.6.1459.
Results Reference
background

Learn more about this trial

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

We'll reach out to this number within 24 hrs